Pharmacology, Toxicology and Pharmaceutical Science
Adverse Drug Reaction
42%
Angiotensin Receptor Antagonist
10%
Antibiotics
32%
Anticoagulant Agent
28%
Antidiabetic Agent
14%
Antiinfective Agent
71%
Antipsychotic
42%
Antiviral Drug
14%
Aripiprazole
12%
Asthma
42%
Calcium Channel Blocker
14%
Chronic Obstructive Lung Disease
42%
Clinical Trial
10%
Cohort Study
42%
Combination Therapy
19%
Comorbidity
42%
Coronavirinae
100%
COVID-19 Vaccine
42%
Dipeptidyl Carboxypeptidase Inhibitor
10%
Disease
10%
Diseases
63%
Diuretics
14%
Doxycycline
42%
Drug Dispensing
14%
Excipient
10%
Immunotherapy
12%
Infection
85%
Ivermectin
39%
Lysine
42%
Multiple Sclerosis
42%
Nanoparticle
42%
Non Small Cell Lung Cancer
42%
Observational Study
68%
Pandemic
85%
Pharmacotherapy
48%
Polypeptide
10%
Prednisolone
46%
Prednisone
12%
Prevalence
79%
Pseudomonas aeruginosa
10%
Randomized Controlled Trial
42%
Repurposing
14%
Risperidone
12%
SARS Coronavirus
85%
Skin Infection
42%
Sodium Glucose Cotransporter 2 Inhibitor
28%
Sulfonylurea
14%
Transdermal
10%
Typical Antipsychotic
42%
Virus Infection
42%
Keyphrases
Adjusted Hazard Ratio
42%
Anticoagulants
28%
Antidiabetic Drugs
14%
Asthma Treatment
42%
Calcium Channel Blockers
14%
Cancer Drugs
42%
Clinically Significant
14%
Commercial Drugs
14%
Community Use
42%
Corticosteroids
28%
COVID-19
57%
COVID-19 Pandemic
53%
COVID-19 Vaccine
42%
Dispensing Pattern
42%
Drug Dispensing
14%
Drug Repurposing
42%
European Studies
42%
Government Response
14%
Government Restrictions
14%
Groningen
24%
Inception Cohort Study
42%
Incidence Rate
14%
Infection Outcome
42%
Interrupted Time Series
42%
Ivermectin
28%
Meta-analysis
42%
National Institutes of Health
42%
Negatively Associated
14%
Netherlands
85%
Non-small Cell Lung Cancer (NSCLC)
42%
Older Adults
42%
Oral Prednisolone
32%
Pandemic Response
14%
Patient-initiated
21%
Prednisolone
28%
Prednisone
21%
Prescription Database
14%
Prevalence Rate
14%
Primary Series
19%
Restriction Policy
14%
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
42%
Severe Outcomes
42%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
28%
Stringency Index
28%
Sulfonylurea
14%
Systematic Meta-analysis
42%
Technology Assessment
42%
Treatment Step
42%
Vaccine Effectiveness
42%
ε-Polylysine
42%
Medicine and Dentistry
ACE Inhibitor
10%
Angiotensin Receptor Antagonist
10%
Asthma
42%
Cancer Therapy
6%
Clinical Trial
10%
Cohort Analysis
42%
COVID-19
58%
COVID-19 Vaccine
42%
Disease
5%
Diseases
6%
Drug Repositioning
5%
Hazard Ratio
24%
Health Status
6%
Hydroxychloroquine
10%
Immunotherapy
12%
Infection
85%
Intensive Care Unit
6%
Intervention Study
5%
Isoprenaline
6%
Ivermectin
10%
Meta-Analysis
85%
Non Small Cell Lung Cancer
42%
Observational Study
16%
Omicron Coronavirus Variant
36%
Prednisolone
18%
Prednisone
12%
Primary Prevention
42%
Proportional Hazards Model
6%
Severe Acute Respiratory Syndrome Coronavirus 2
85%
Statin
5%
Survival Analysis
6%
Systematic Review
85%
Targeted Therapy
12%
Telemedicine
6%
Vulnerable Population
6%
